Omega-3 fatty acids, CoQ10, berberine, red yeast rice, magnesium, garlic extract — the cardiovascular supplement category is broad and well-populated. It's also one where FDA enforcement is consistent and where the distinction between structure/function claims and prohibited disease claims has been tested in dozens of warning letters.
What FDA Permits for Heart and Cardiovascular Claims
Under 21 CFR 101.93(f), cardiovascular supplements may make structure/function claims describing how ingredients support normal heart and circulatory function. These are generally permissible:
"Supports healthy heart function"
"Promotes healthy circulation"
"Supports cardiovascular health"
"Helps maintain healthy blood pressure already within the normal range"
"Supports healthy cholesterol levels already within the normal range"
"Promotes healthy triglyceride levels"
"Supports healthy arterial flexibility"
"Promotes healthy blood flow"
The qualifiers "already within the normal range" are load-bearing in these claims. They establish that the product supports normal function — it doesn't correct a disease state.
Where Heart Claims Become Disease Claims
Prohibited under 21 CFR 101.93(g):
"Reduces risk of heart disease" — disease prevention claim (heart disease is a named condition)
"Lowers high blood pressure" — treating hypertension (a named disease)
"Reduces high cholesterol" — treating hypercholesterolemia (a disease state)
"Helps prevent heart attacks" — named cardiac event, treatment/prevention claim
"Reduces cardiovascular risk" — implies prevention of cardiovascular disease
"Improves coronary artery function in people with blockages" — references a disease state
"Reduces inflammation in arteries" — arterial inflammation is associated with specific cardiovascular disease states
"Helps prevent atherosclerosis" — named disease
The "already within the normal range" construction is critical. "Supports healthy cholesterol levels" is a structure/function claim. "Supports healthy cholesterol levels already within the normal range" makes explicit that the claim is about maintaining normal function. "Lowers cholesterol" without that qualifier implies correcting an elevated (disease) state.
Authorized Health Claims: A Narrow Exception
The FDA has authorized specific health claims for certain nutrients related to cardiovascular disease — a separate category from structure/function claims. Authorized health claims are allowed to make disease-risk-reduction statements, but only for nutrients and foods that meet specific qualifying criteria.
The omega-3 fatty acid heart disease claim (established under 21 CFR 101.83) is one example. This claim allows qualified language about EPA and DHA's potential role in reducing the risk of coronary heart disease — but it requires the specific disclaimer that the evidence is not conclusive, and it only applies to products meeting specific content thresholds.
This is not a blanket permission for all omega-3 supplements to make heart disease risk-reduction claims. The claim requires meeting specific qualifying conditions and using the exact authorized language. Brands that riff on this claim without meeting the technical requirements are making unauthorized disease claims.
Red Yeast Rice: A Special Enforcement Target
Red yeast rice occupies one of the most complex positions in supplement regulatory history. It naturally contains monacolin K — chemically identical to lovastatin, an FDA-approved prescription drug for lowering cholesterol. The FDA has taken the position that red yeast rice products containing significant amounts of monacolin K are unapproved drugs, not dietary supplements.
Brands selling red yeast rice and making cholesterol-lowering claims face compound exposure: a potential drug claim violation and a potential illegal drug ingredient issue simultaneously. This is a category where the compliance review needs to go beyond claim language to ingredient legal status.
Berberine and Blood Pressure
Berberine has growing clinical evidence for effects on blood pressure and blood sugar. Structure/function claims for berberine should describe support for normal cardiovascular function — not treatment of hypertension. The same evidence that makes berberine interesting scientifically (meaningful effects on blood pressure and glucose metabolism) also makes its claims high-risk if not carefully framed.
Truli scans heart health claims against 21 CFR 101.93 and flags cholesterol, blood pressure, and cardiovascular disease language that crosses from structure/function support into disease treatment territory.
Heart health claims are high-stakes in every direction
The consumer appeal is real, the enforcement scrutiny is real, and the authorized health claim framework creates both an opportunity and a trap. Brands in this category need claim-by-claim review against the specific regulatory standards for each ingredient — not a general "sounds like structure/function to me" assessment.
A note from Truli: Truli is not a law firm, and this article does not constitute or contain legal advice or create an attorney-client relationship. When determining your obligations and compliance with respect to relevant laws and regulations, you should consult a licensed attorney.
